The Trump Administration recently announced the selection of Norman E. “Ned” Sharpless, MD, as incoming director of the National Cancer Institute (NCI) under the National Institutes of Health (NIH). He will replace Douglas Lowy, MD, who has served as NCI’s acting director since April 2015.
Dr. Sharpless is a well-known oncology and genetics researcher currently serving at the University of North Carolina (UNC) as director of the Lineberger Comprehensive Cancer Center. He previously co-founded G1 Therapeutics, a clinical-stage company developing small-molecule therapies to address unmet needs in oncology.
In a June 12 official statement, Francis S. Collins, MD, PhD, Director of NIH, indicated that he knows Dr. Sharpless and is “very pleased” with the selection.